How India Exports Leflunomide to the World

In the United States, leflunomide received its initial approval under the brand name Arava on September 10, 1998, as documented in the FDA's Drug Approval Package. Subsequently, numerous Abbreviated New Drug Applications (ANDAs) for generic versions have been approved, reflecting a competitive market landscape. The FDA's Orange Book lists multiple approved ANDAs for leflunomide, indicating its widespread acceptance and availability in the U.S. market. Notably, the United States accounted for 40.5% of India's leflunomide exports between 2022 and 2026, underscoring the significance of the U.S. market for Indian exporters.

In the European Union, leflunomide was first authorized under the brand name Arava on September 2, 1999, for the treatment of active rheumatoid arthritis and psoriatic arthritis. Generic versions, such as Leflunomide Teva, received marketing authorization on March 10, 2011. However, due to the absence of marketing within three years, Leflunomide Teva's authorization lapsed on March 10, 2014, in accordance with the EU's "sunset clause" provisions. Similarly, Repso, another generic version, had its marketing authorization withdrawn on July 19, 2017, at the request of the marketing authorization holder for commercial reasons. Despite these withdrawals, other generic versions like Leflunomide Zentiva remain authorized and available in the EU market. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with the EU's regulatory standards, ensuring that leflunomide products meet stringent quality and safety requirements.

Leflunomide is included in the World Health Organization's Model List of Essential Medicines, highlighting its importance in treating rheumatoid arthritis. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality parameters across different regions.

In India, leflunomide is classified as a Schedule H drug under the Drugs and Cosmetics Act, necessitating a prescription for its dispensation. The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of essential medicines; however, as of March 2026, leflunomide is not listed under the Drugs (Prices Control) Order (DPCO), indicating no ceiling price is currently imposed. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations.

The primary patents for leflunomide have expired, leading to the availability of multiple generic versions globally. This has intensified competition among manufacturers, contributing to the drug's affordability and accessibility.

In June 2025, the NPPA conducted a review of essential medicines pricing, but leflunomide remained outside the purview of price control, allowing market-driven pricing to continue. In September 2025, the FDA approved a new generic version of leflunomide, further enhancing market competition and potentially influencing export dynamics for Indian manufacturers. In December 2025, the EMA updated its guidelines on the manufacturing of active pharmaceutical ingredients (APIs), emphasizing stricter compliance with Good Manufacturing Practices (GMP), which Indian exporters must adhere to for continued access to the European market.

These developments underscore the dynamic regulatory environment surrounding leflunomide, necessitating continuous monitoring by stakeholders to ensure compliance and strategic market positioning.

Leflunomide, an immunomodulatory drug primarily used to treat rheumatoid arthritis, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where India imports approximately 60–70% of its KSMs and intermediates from China, creating significant supply chain vulnerabilities.

Recent disruptions have underscored these risks. In July 2018, environmental regulations led to the shutdown of several Chinese chemical plants, causing a ripple effect that impacted global pharmaceutical supply chains, including Indian API manufacturers. Such events highlight the fragility of over-reliance on a single country for critical raw materials.

The export market for Leflunomide from India is notably concentrated. The top five exporters—Zydus Lifesciences Limited, Torrent Pharmaceuticals Ltd, Kusum Healthcare Private Limited, Emcure Pharmaceuticals Limited, and Alembic Pharmaceuticals Limited—collectively account for 71.4% of total exports. Zydus Lifesciences Limited alone holds a 29.7% share, indicating a significant single-source risk.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at promoting domestic manufacturing of critical KSMs, Drug Intermediates (DIs), and APIs. As of December 2025, the scheme has led to the establishment of manufacturing capacities for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore.

Global shipping routes critical to pharmaceutical exports, such as the Red Sea and the Strait of Hormuz, have experienced disruptions due to geopolitical tensions. These disturbances can delay shipments and increase transportation costs, affecting the timely delivery of pharmaceuticals like Leflunomide.

Additionally, escalating tensions between the United States and China have raised concerns about potential trade restrictions or tariffs on pharmaceutical raw materials. Such measures could further strain the supply chain, given India's reliance on Chinese KSMs. While specific FDA or EMA shortage alerts for Leflunomide have not been issued recently, the interconnectedness of global supply chains means that disruptions in one area can have cascading effects on drug availability.

• Diversify Raw Material Sources: Encourage Indian API manufacturers to source KSMs from multiple countries to reduce dependency on a single nation.

• Enhance Domestic Production: Leverage the PLI scheme to further boost domestic manufacturing of critical KSMs and APIs, thereby strengthening supply chain resilience.

• Monitor Geopolitical Developments: Establish a dedicated task force to track geopolitical events that could impact shipping routes and raw material availability, enabling proactive risk management.

• Strengthen Supplier Relationships: Develop strategic partnerships with multiple suppliers to ensure a steady supply of raw materials and finished products.

• Implement Robust Inventory Management: Maintain adequate buffer stocks of critical raw materials and finished products to cushion against potential supply chain disruptions.

RISK_LEVEL: MEDIUM